Genta, National Cancer Institute deal

A committee of the NCI voted in favor of funding and conducting preclinical studies of GNTA’s G3139 Anticode (antisense) drug. Pending the outcome of the studies, the institute would sponsor Phase I trials in several solid tumors. GNTA is negotiating an agreement under which the institute would recover the costs of running both preclinical and clinical studies. ...